Literature DB >> 8834401

Intrastriatal and intraventricular infusion of brain-derived neurotrophic factor in the cynomologous monkey: distribution, retrograde transport and co-localization with substantia nigra dopamine-containing neurons.

E J Mufson1, J S Kroin, Y T Liu, T Sobreviela, R D Penn, J A Miller, J H Kordower.   

Abstract

The distribution and retrograde transport of brain-derived neurotrophic factor was examined using magnetic resonance imaging guided stereotaxic intracerebroventricular and intrastriatal infusion in the cynomologous monkey. Two intracerebroventricular animals were infused with brain-derived neurotrophic factor at a dose of 3 micrograms/h for 21 and 28 days. A third intracerebroventricular animal received sequential infusions of 15, 30 and 60 micrograms/h brain-derived neurotrophic factor each for seven days using an Alzet 2002 minipump. For the multiple intrastriatal animals (n = 5) a dose of 3 micrograms/h was infused into each site. One intrastriatal monkey was infused with vehicle solution of 10 mM phosphate-buffered saline pH 7.4 for 14 days resulting in no brain-derived neurotrophic factor immunoreactivity. Following the lower dose intracerebroventricular infusion, brain-derived neurotrophic factor immunoreactivity was confined to the ventricular ependymal layer. In the sequential higher dose intracerebroventricular case, the cannula was located mainly within the lateral ventricle, although there was damage to the ependymal wall and adjacent caudate nucleus. Brain-derived neurotrophic factor immunoreactivity revealed spread of injectate within the ipsilateral and to a lesser extent the contralateral caudate nucleus, septum, orbital cortex and ventricular ependymal wall. In this case, retrogradely labelled brain-derived neurotrophic factor neurons were found within the parafascicular thalamus and substantia nigra, pars compacta, as well as within cortex, vertical limb of the diagonal band and nucleus basalis. Brain-derived neurotrophic factor intrastriatal infusion retrogradely labelled perikarya within sensory motor cortex, parafascicular thelamus and substantia nigra, pars compacta. Sections from these cases dual-immunoreacted for brain-derived neurotrophic factor and tyrosine hydroxylase, the synthesizing enzyme for dopamine, revealed a subpopulation of pars compacta dopaminergic neurons which contained retrogradely transported brain-derived neurotrophic factor. These findings indicate that a select subgroup of nigral dopamine neurons retrogradely transport brain-derived neurotrophic factor in the primate. Furthermore it remains to be determined whether select nigral cells are responsive to the trophic influences of brain-derived neurotrophic factor in the normal and neuropathologic condition.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8834401     DOI: 10.1016/0306-4522(95)00431-9

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  8 in total

1.  Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models.

Authors:  Heath D Schmidt; Ronald S Duman
Journal:  Neuropsychopharmacology       Date:  2010-08-04       Impact factor: 7.853

2.  Spatiotemporal presentation of exogenous SDF-1 with PLGA nanoparticles modulates SDF-1/CXCR4 signaling axis in the rodent cortex.

Authors:  D Dutta; K Hickey; M Salifu; C Fauer; C Willingham; S E Stabenfeldt
Journal:  Biomater Sci       Date:  2017-07-25       Impact factor: 6.843

Review 3.  Agile delivery of protein therapeutics to CNS.

Authors:  Xiang Yi; Devika S Manickam; Anna Brynskikh; Alexander V Kabanov
Journal:  J Control Release       Date:  2014-06-21       Impact factor: 9.776

Review 4.  The lighter side of BDNF.

Authors:  Emily E Noble; Charles J Billington; Catherine M Kotz; ChuanFeng Wang
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-02-23       Impact factor: 3.619

Review 5.  Delivery of neurotrophic factors to the central nervous system: pharmacokinetic considerations.

Authors:  R G Thorne; W H Frey
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

6.  Tropomyosin-related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward.

Authors:  Danielle L Graham; Vaishnav Krishnan; Erin B Larson; Ami Graham; Scott Edwards; Ryan K Bachtell; Diana Simmons; Lana M Gent; Olivier Berton; Carlos A Bolanos; Ralph J DiLeone; Luis F Parada; Eric J Nestler; David W Self
Journal:  Biol Psychiatry       Date:  2008-11-06       Impact factor: 13.382

Review 7.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

Review 8.  NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson's disease.

Authors:  Daniel Martinez-Fong; Michael J Bannon; Louis-Eric Trudeau; Juan A Gonzalez-Barrios; Martha L Arango-Rodriguez; Nancy G Hernandez-Chan; David Reyes-Corona; Juan Armendáriz-Borunda; Ivan Navarro-Quiroga
Journal:  Nanomedicine       Date:  2012-03-07       Impact factor: 5.307

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.